|
Mar 25
|
30 Countries with Highest Proportion of Older Adults
|
|
Mar 24
|
1 Magnificent Dividend Stock to Buy and Hold
|
|
Mar 22
|
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Mar 19
|
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
|
|
Mar 18
|
Novartis (NVS) Stock Dips While Market Gains: Key Facts
|
|
Feb 14
|
30 Countries with Highest Standard of Living Ranked by GDP (PPP) Per Capita
|
|
Feb 14
|
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
|
|
Feb 10
|
30 Most Valuable Drug Companies in 2024
|
|
Feb 9
|
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
|
|
Feb 9
|
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
|
|
Feb 9
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
|
|
Jan 19
|
Bill Gates, will.i.am, top execs on AI: Davos best moments
|
|
Jan 19
|
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
|
|
Jan 19
|
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
|
|
Jan 19
|
Novartis details first-line data for radiopharma drug Lutathera
|
|
Jan 18
|
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Jan 18
|
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
|
|
Jan 18
|
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
|
|
Jan 17
|
Bill Gates, Nasdaq, Verizon CEOs on AI: Davos highlights
|
|
Jan 17
|
Novartis CEO explains how AI will impact drug development
|